Home
About US
    About GenSci
    Our Values
    Production Sites
    Counterfeiting
    Contact Us
Science
    R&D
        R&D Centers
     Technology
        Driven by state-of-the-art Technology Platforms
Collaborations & Partnerships
News
    Press Releases
        Gensci Showcases Women's Health and Immunology Innovations at BIO 2025
        NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral Suspension
        Gensci Showcases BsADC Pipeline at 4th World ADC Asia Summit
        The FDA has Cleared the IND Application for GenSci128 for TP53 Y220C-Mutated Solid Tumors
        GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone Leader
        Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.
        Episil® Launched in China: A Breakthrough Solution for Oral Mucositis
        GenSci Submits Another Blockbuster Product for Market Approval
        Clinical Trial Commencement of GenSci120 Injection Approved
        GenSci Showcases the Latest R&D Achievements at J.P. Morgan
        NMPA Approves the PD-1 agonist GenSci120 for Clinical Trials Commencement
        Pediatric Golden Cough-Relief Granules Approved, a Superior Clinical Solution for Acute Cough in Children
        GenSci Invites You to Meet Us at Arab Health 2025
        Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024
        World ADC San Diego 2024: GenSci showcases two innovative pipeline programs
        Welcome to Visit Us at MEDICA 2024
        GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Action
        Meet GenSci at CPhI Milan 2024
        GenSci showcases the innovative pipelines at ChinaBio®
        GenSci Invites You to Meet Us at Pharmedi Vietnam 2024
        GenSci098 Injection Obtains Implied License For Clinical Trials of FDA
        Jintrolong® New Dosage Form of Long-acting Somatropin Injection Approved
        Clinical Trial Commencement of GenSci098 Injection Approved
        Zhejiang University – GenSci Joint Research Center of Children’s Health established
        NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection Accepted
        R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation Agreement
        GenSci Invites you to join us in CPHI South East Asia 2024
        China's First Aqueous Solution Progesterone Injection, Jin Sai Xin® Approved
        GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia®
        Visit GenSci at CPhI China 2024
        NMPA Approves Genakumab Injection for Clinical Trial Commencement
        Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024
        R&D Progress: NMPA Approves Genakumab to the Market
        GenSci Launches Global Innovation Hub in Shanghai
Sustainability